Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Viral hepatitis

Innovation is needed to increase viral hepatitis testing globally

Nature Reviews Gastroenterology & Hepatology volume 21, pages 3–4 (2024)Cite this article

Subjects

Innovative approaches to increase testing are needed to achieve the 2030 hepatitis B and hepatitis C elimination targets. Zhang et al., partnering with local community organizations, successfully used a pay-it-forward approach to increase hepatitis B and hepatitis C testing among men who have sex with men in China.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Pay-it-forward mechanism.

References

  1. World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. WHO https://www.who.int/publications/i/item/9789240053779 (2022).

  2. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. WHO https://apps.who.int/iris/handle/10665/246177 (2016).

  3. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact. WHO https://www.who.int/publications/i/item/9789240027077 (2021).

  4. Cui, F. et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol. Hepatol. 8, 332–342 (2023).

    Article  PubMed  Google Scholar 

  5. Howell, J. et al. A global investment framework for the elimination of hepatitis B. J. Hepatol. 74, 535–549 (2021).

    Article  PubMed  Google Scholar 

  6. Scott, N. et al. A model of the economic benefits of global hepatitis C elimination: an investment case. Lancet Gastroenterol. Hepatol. 5, 940–947 (2020).

    Article  PubMed  Google Scholar 

  7. Zhang, Y. et al. Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial. Nat. Med. 29, 2241–2247 (2023).

    Article  CAS  PubMed  Google Scholar 

  8. Pedrana, A. et al. Global hepatitis C elimination: an investment framework. Lancet Gastroenterol. Hepatol. 5, 927–939 (2020).

    Article  PubMed  Google Scholar 

  9. EC Australia. Annual Report Year 4, 2022. Burnet Institute https://www.burnet.edu.au/media/o1opjflt/ec-australia_annual-report-year-4-2022_v1.pdf (2023).

  10. Burnet Institute & Kirby Institute. Australia’s progress towards hepatitis C elimination: annual report 2022. Burnet Institute https://www.burnet.edu.au/knowledge-and-media/research-reports-plus-policy-briefs/australia-s-progress-towards-hepatitis-c-elimination-annual-report-2022/ (2022).

Download references

Acknowledgements

The authors acknowledge the contributions of C. Aitken (Burnet Institute; manuscript editing).

Author information

Authors and Affiliations

  1. Disease Elimination, Burnet Institute, Melbourne, Victoria, Australia

    Margaret E. Hellard & Alisa Pedrana

  2. School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

    Margaret E. Hellard & Alisa Pedrana

  3. Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Victoria, Australia

    Margaret E. Hellard

  4. Doherty Institute and School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia

    Margaret E. Hellard

Authors
  1. Margaret E. Hellard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alisa Pedrana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret E. Hellard.

Ethics declarations

Competing interests

The institution of M.E.H. and A.P. receives funding from Gilead and Abbvie for investigator-initiated research unrelated to this work. A.P. has received honoraria for consultancies from Gilead, unrelated to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hellard, M.E., Pedrana, A. Innovation is needed to increase viral hepatitis testing globally. Nat Rev Gastroenterol Hepatol 21, 3–4 (2024). https://doi.org/10.1038/s41575-023-00865-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-023-00865-1

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing